Evofem investor presentation
Web12400 High Bluff Drive, Suite 600 San Diego, California 92130 1.858.550.1900 WebInvestors. Investor Overview; Events & Presentations; Press Releases; Stock Information; Financial Information. SEC Filings; Analyst Coverage; Corporate Governance. …
Evofem investor presentation
Did you know?
WebEvofem Biosciences has raised a total of $470.8M in funding over 16 rounds. Their latest funding was raised on May 20, 2024 from a Post-IPO Equity round. Evofem Biosciences is registered under the ticker NASDAQ:EVFM . Evofem Biosciences is funded by 12 investors. Keystone Capital and Adjuvant Capital are the most recent investors. WebJun 8, 2024 · statements in this presentation are qualified in their entirety by this cautionary statement. Evofem Biosciences (Nasdaq: EVFM) Commercial-stage biopharmaceutical …
WebEvofem Biosciences has raised a total of $470.8M in funding over 16 rounds. Their latest funding was raised on May 20, 2024 from a Post-IPO Equity round. Evofem Biosciences … WebFeb 15, 2024 · © 2024 Evofem Biosciences, Inc. For investor discussions only. Page 9 81% INCREASE IN DISPENSED UNITS AND 69% TRxINCREASE IN Q4 VS. Q3 Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 …
WebNov 27, 2024 · Evofem’sfilings from time to time with the U.S. Securities and Exchange Commission. The forward looking statements in this presentation represent Evofem’sviews only as of the date of this presentation, November 27, 2024, and Evofem undertakes no obligation to update or review any WebSep 12, 2024 · The investor presentation cites a multi-billion dollar market opportunity for current and late stage investigational indications. Evofem has set the bar by which their …
WebMar 21, 2024 · •Evofem’s ability to reduce its operating expenses, rely on existing cash reserves to fund its current development plans and operations, and to raise additional capital when needed •The success of Evofem’s ACA strategy •Evofem’sreliance on third-party providers, such as third-party manufacturers and clinical research organizations
WebApr 6, 2024 · Presentation Operator MessageOperator Good afternoon and welcome to the Evofem Biosciences investor update call. I'll turn the call over to Amy Raskopf, Evofem Biosciences' Vice President of Investor... April 7, 2024 teas twuWebMay 6, 2024 · The forward looking statements in this presentation represent Evofem's views only as of the date of this presentation, May 6, 2024, and Evofem expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evofem's … spanish pc keyboardWebEvofem Headquarters - 12400 High Bluff Drive Suite 600 San Diego, California 92130. ... Investor Overview; Events & Presentations; Press Releases; Stock Information; Financial Information. SEC Filings; ... If you are an investor, please use the Investor Contact form to ensure your message is routed properly. teasu 12pcs pearl stringWebJul 28, 2024 · Evofem Biosciences to Report Second Quarter 2024 Results and Provide Corporate Update on Thursday, August 4, 2024 - read this article along with other careers information, tips and advice on BioSpace Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights … spanish peacock winery jamul californiaWebSaundra Pelletier has served as Chief Executive Officer, President and Executive Director of Evofem Biosciences since February 2015, and as interim Chair of the Board since November 2024 following the resignation of our former Chair due to health reasons. Ms. Pelletier has been responsible for the company’s growth and evolution, and she led ... tea subscription fresh runnersWeb5 ©2024 Evofem Biosciences, Inc.©2024 Evofem Biosciences, Inc. For investor discussions only. The Unmet Need for a Non-Hormonal Contraceptive. Of the ~47M women at-risk for pregnancy ~17M segment out as potential adopters ~30M. 9M. 8M ~17M • Seeking/open to alternatives to hormonal contraception teas typesWebMay 4, 2024 · Greetings, and welcome to the Evofem Biosciences’ First Quarter of 2024 Financial Results Call. At this time, all participants are in a listen only mode. A brief … tea summary of finances